Put companies on watchlist
M1 Kliniken AG
ISIN: DE000A0STSQ8
WKN: A0STSQ
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

M1 Kliniken AG · ISIN: DE000A0STSQ8 · EQS - adhoc news (69 News)
Country: Germany · Primary market: Germany · EQS NID: 1151538
30 November 2020 03:30PM

M1 Kliniken AG: Mr. Patrick Brenske joins the board of HAEMATO AG. Promotion of the product business as core task of the integration of the Haemato Group into the M1 Kliniken AG - Group


DGAP-Ad-hoc: M1 Kliniken AG / Key word(s): Personnel/Miscellaneous
M1 Kliniken AG: Mr. Patrick Brenske joins the board of HAEMATO AG. Promotion of the product business as core task of the integration of the Haemato Group into the M1 Kliniken AG - Group

30-Nov-2020 / 15:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


M1 Kliniken AG: Mr. Patrick Brenske joins the board of HAEMATO AG. Promotion of the product business as core task of the integration of the Haemato Group into the M1 Kliniken AG - Group

Berlin, 30.11.2020 - M1 Kliniken AG announces that as of today Mr. Patrick Brenske will join the Management Board of HAEMATO AG. At the same time, Mr. Brenske will resign from the Management Board of M1 Kliniken AG, with Dr. Walter von Horstig from now on acting as sole member of the Management Board. Mr. Brenske will continue to advise M1.

Before joining M1 Kliniken AG, Mr. Patrick Brenske had already worked for the Haemato Group for about eight years as Head of Purchasing and Sales and led the group from a turnover in the small single-digit million range towards an annual turnover of close to 300 million euros. The attainment of the manufacturing licence in accordance with § 13 AMG (German medicines act) was one of the main drivers of HAEMATO's product business.

After the acquisition of almost 50% of HAEMATO AG by M1 Kliniken AG by mid of 2020, M1 Kliniken AG follows the strategy of integrating the value chain and strengthening the product business. This offers potentials for added value - while ensuring quality.

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the M1 Schlossklinik für plastische und ästhetische Chirurgie in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving forward its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England and Australia. In addition, the Group markets high-quality products under the brands "M1 Select" and "M1 Aesthetics" to private customers as well as doctors, pharmacies and wholesalers.

Contact us: M1 Klinken AG
Grünauer Strasse 5; D-12557 Berlin
T: +49 (0) 30 34 74 74 - 414
M: ir@m1-kliniken.de
W: www.m1-kliniken.de


30-Nov-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
E-mail: ir@m1-kliniken.de
Internet: https://www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1151538

 
End of Announcement DGAP News Service

1151538  30-Nov-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1151538&application_name=news&site_id=boersengefluester_html
Visual performance / price development - M1 Kliniken AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.